BioStem Technologies reported a 55% revenue decline in Q4 2025 to $10.1 million due to reimbursement challenges and competition, but achieved a strong 97% gross margin. The company completed the acquisition of BioTissue Holdings' surgical and wound assets in January 2026, expanding its product range and sales force into hospital markets. Despite a net loss of $11.3 million in Q4, BioStem expects growth in its hospital business and stabilization in physician office markets in the second half of 2026. The company is also preparing for a Nasdaq uplisting with audited financials forthcoming.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
